#HVO hVIVO PLC – £6m Influenza HCT contract signed May 7, 2026 – Posted in: hVIVO (HVO)

London, UK – 7 May 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces that it has signed a £6 million Clinical Trial Agreement (“CTA”) to conduct a human challenge (HCT) trial on behalf of a clinical-stage biopharmaceutical company developing novel therapies for respiratory viral diseases. The trial will evaluate the monoclonal antibody using the hVIVO Influenza Human Challenge Study Model. This will be a randomised, double-blinded placebo-controlled trial…

#POLB Poolbeg Pharma PLC – POLB 001 to feature in CRS research programme December 8, 2025 – Posted in: Poolbeg Pharma (POLB)

8 December 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the POLB 001 TOPICAL trial is to feature in a groundbreaking cancer immunotherapy-induced cytokine release syndrome (“CRS”) research programme. Poolbeg will act as the lead business partner, alongside Johnson & Johnson and other partners, on The University of Manchester and The Christie NHS Foundation Trust research programme supported by…

#HVO hVIVO PLC – Positive data from novel human challenge models November 11, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces key insights from its scientific presentations at the 10th European Scientific Working Group on Influenza (“ESWI”) Conference in Valencia, and the World Vaccine Congress Europe in Amsterdam, which both took place in October 2025. hVIVO presented positive data from a number of newly developed human challenge models reinforcing hVIVO’s continued world-leading capabilities in accelerating…

#POLB Poolbeg Pharma PLC – Result of upsized oversubscribed BookBuild Offer May 23, 2025 – Posted in: Poolbeg Pharma (POLB)

Result of upsized and oversubscribed BookBuild Offer · Conditionally raised gross proceeds of £150,000 from the upsized and oversubscribed BookBuild Offer · Total gross proceeds conditionally raised pursuant to the Fundraising therefore increased to £4.865 million · Use of net proceeds from the Fundraising: o Phase 2a clinical trial for POLB 001, targeting prevention of cancer immunotherapy-induced Cytokine Release Syndrome (CRS) o Oral GLP-1 proof-of-concept clinical trial o Cash runway extended through to 2027 Poolbeg Pharma…

#HVO hVIVO PLC – Holding(s) in Company January 31, 2025 – Posted in: hVIVO (HVO)

hVIVO was notified by Rathbones Investment Management Ltd on 29th January 2025 that it has increased its shareholding to 87,847,709 shares (12.911%).

#HVO hVIVO PLC – £3.2m hLAB project January 21, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hLAB, the Group’s standalone virology and immunology laboratory service provider, has signed a new £2.7m contract with a US-based biotechnology client bringing the total value of this project to date to £3.2m. As part of this new contract, hLAB will act as the only contracted virology…

#HVO hVIVO PLC – Positive results from RSV human challenge trial October 7, 2024 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the announcement by Enanta Pharmaceuticals (“Enanta”), reporting positive topline results from a Phase 2a Respiratory Syncytial Virus (“RSV”) human challenge trial (“HCT”) in healthy adults conducted by hVIVO for EDP-323, its second RSV antiviral candidate. EDP-323, a novel, oral, direct-acting antiviral in development for RSV infection, has…

#HVO hVIVO PLC – Presentation at World Vaccine Congress March 29, 2023 – Posted in: hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that Dr Andrew Catchpole, Chief Scientific Officer, will be delivering a presentation at the World Vaccine Congress, Washington D.C., United States. Full details of the presentation are included below: Title Challenge Studies – can the results be expected to mimic…

#HVO hVIVO PLC – £5.2m RSV contract and Notice of Trading update January 4, 2023 – Posted in: Blog, hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO) (formerly Open Orphan plc), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has signed a £5.2m contract with a global biotechnology company headquartered in Asia Pacific to test their respiratory syncytial virus (“RSV”) vaccine candidate, using hVIVO’s established RSV Human Challenge Study Model. The Company also announces that it will provide…